ClinicalTrials.gg
RecruitingNCT04414046Updated Jul 1, 2026

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

A Phase 2 interventional study of Haploidentical Hematopoietic Cell Transplantation in Primary Immune Deficiency Disorders and Metabolic Disease, sponsored by Johns Hopkins All Children's Hospital. Recruiting at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Johns Hopkins All Children's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Primary Immunodeficiency Diseases with a site in United States — 25 open to participants now, 34 under way, 4 of them phase 3. Primary Immunodeficiency Diseases · United States.

Planned enrollment
61st of 75
17 · median 40
Started
2020
with 8 others
Phase 2
12 of 108
7 open now
Primary completion
2027-06
later than 12 of 28 live
Registered
82nd of 108
by date

Among the 108 studies in Primary Immunodeficiency Diseases with a site in United States, this one is the 61st largest by planned enrollment of the 75 interventional ones that give a count, is one of 9 that started in 2020, is one of 12 in phase 2, reaches primary completion later than 12 of the 28 other live ones, and was the 82nd registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

25 of the 108 studies in Primary Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Primary Immunodeficiency Diseases with a site in United States, or all of them as a file.
02

Study summary

This research is being done to learn if a new type of haploidentical transplantation using TCR alpha beta and CD19 depleted stem cell graft from the donor is safe and effective to treat the patient's underlying condition. This study will use stem cells obtained via peripheral blood or bone marrow from parent or other half-matched family member donor. These will be processed through a special device called CliniMACS, which is considered investigational.

03

Conditions studied

  • Primary Immune Deficiency Disorders
  • Metabolic Disease
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Patient with any form of primary immune deficiency/dysregulatory disorders characterized by aberrant immune function, abnormal hematopoiesis, systemic or organ specific autoimmunity and/or non-malignant lymphoproliferation. This includes, but not limited to:

    I. Disorders of phagocytes: Chronic granulomatous disease, Leukocyte adhesion deficiency, defects of IL-10 pathway, MonoMac syndrome

    II. Defects of cellular and humoral immunity: Severe Combined Immunodeficiency Disorder (infants with classic SCID up to 2 years of age will be excluded due to other open protocol), X-linked hyper-IgM syndrome, DOCK8 deficiency, ZAP70 deficiency, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, NEMO deficiency.

    III. Disorder of immune dysregulation: Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, CTLA4 deficiency, LRBA deficiency, STAT1 GOF, STAT3 GOF, X-linked lymphoproliferative disease etc.

    IV. Other PIDs and immune dysregulatory disorders who can be benefitted by HCT as deemed appropriate by the PI and the treating immunologist.

  2. Histiocytic disorders including hemophagocytic lymphohistiocytosis (familial HLH (types 1-5), secondary HLH ( to therapy or with recurrent episodes of hyper inflammation) and multisystem refractory Langerhans cell histiocytosis.
  3. Metabolic disorders that could improve or stabilize after stem cell transplantation such as mucopolysaccharidoses, neurodegenerative disorders, osteopetrosis, etc.

Inclusion Criteria:

  1. Patient has a suitable genotypic identical match of 5/10. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1.
  2. Patients must have adequate organ function measured by:

    1. Cardiac: asymptomatic or if symptomatic then at rest must be ≥ 40% or SF ≥ 26%
    2. Pulmonary: asymptomatic or if symptomatic DLCO ≥ 40% of predicted (corrected for ) or pulse oximetry ≥ 92% on room air if the patient is unable to perform pulmonary function testing.
    3. Renal: (CrCl) or (GFR) must be > 50 mL/min/1.73 m2.
    4. Hepatic: Serum conjugated (direct) \< 2.0 x for age; and ALT \< 5.0 x ULN for age.
    5. or Lansky (age-dependent) performance score ≥ 50
  3. Signed written

Exclusion Criteria:

  1. Participants who have an HLA-matched sibling who is able and willing to donate bone marrow. Patients with a HLA-matched unrelated donors are not excluded.
  2. Pregnant or breastfeeding females.
  3. Patient has or uncontrolled fungal, bacterial or viral infections.
  4. Patient has received prior solid organ transplant.
  5. Patient has active (> grade II) or chronic extensive GVHD due to a previous allograft at the time of inclusion.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (estimated)

Study arms

  • Experimental
    TCR alpha beta T cell depletion

    The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol

    Biological: Haploidentical Hematopoietic Cell Transplantation

Interventions

  • BiologicalHaploidentical Hematopoietic Cell Transplantation

    TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation

06

What researchers measure

Primary outcomes

  1. Incidence of successful donor engraftment

    The incidence of engraftment at day 100 will be described based on donor chimerism in the whole blood and or fractions sorted for T-cell and myeloid subsets. The donor chimerism will be scored as autologous reconstitution (\< 5% donor), mixed chimerism (5-49%=low mixed, 50-95%=high mixed), \> 95%=full donor chimerism.

    Time frame: Day 100 after transplantation

Secondary outcomes

  1. Overall survival and Event-free survival

    Overall survival is defined as the time of enrollment to death from any cause or last follow up. Event-free survival is defined as the time of enrollment to death, primary or secondary graft failure, graft failure necessitating a second HCT procedure, DLI or stem cell boost given for treatment of falling chimerism, or disease recurrence

    Time frame: Up to 2 years post transplant

  2. Kinetics of neutrophil engraftment

    Neutrophil engraftment defined as absolute neutrophil count ≥500/μL for 3 consecutive measurements on different days

    Time frame: Up to 42 days post transplant

  3. Kinetics of platelet engraftment

    Platelet engraftment defined as sustained platelet count \>20,000/μL and \>50,000//μL with no platelet transfusions in the preceding seven days.

    Time frame: Up to 42 days post transplant

  4. Transplant-related mortality

    Rate of transplant-related mortality

    Time frame: Up to 100 days post transplant

  5. Acute grade II-IV GvHD

    Incidence and severity of acute graft versus host disease

    Time frame: Up to 2 years post transplant

  6. Chronic GvHD

    Incidence and severity of chronic graft versus host disease

    Time frame: Up to 2 years post transplant

  7. Primary graft failure

    Rates of primary graft failure

    Time frame: Up to 2 years post transplant

  8. Secondary graft failure

    Rates of secondary graft failure

    Time frame: Up to 2 years post transplant

  9. Transplant-related complications

    Frequency of transplant-related complications following transplantation

    Time frame: Up to 2 years post transplant

  10. Transplant-related infections

    Frequency of transplant-related infections following transplantation

    Time frame: Up to 2 years post transplant

  11. Cellular and Immunological reconstitution by laboratory evaluations

    The recovery of different lymphocyte subpopulation (CD3+; CD4+; CD8+; CD3+CD45RA+and CD45RO; TCR alpha beta; TCR gamma delta; CD19+)

    Time frame: Up to 2 years post transplant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Jun 2027, 83 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2020
First posted
Jun 4, 2020
StartActual
Jul 22, 2020
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04414046
Lead sponsor
Johns Hopkins All Children's Hospital
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Jul 22, 2020
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Jade Hanson, MSN
Contact
jade.hanson@jhmi.edu
7277676468
Deepak Chellapandian, MD
principal investigator · Johns Hopkins All Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion